SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns 
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Anta Sports Expands Global Footprint With Strategic Puma Stake 
Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
Samsung Electronics Shares Jump on HBM4 Mass Production Report 
Kroger Set to Name Former Walmart Executive Greg Foran as Next CEO 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering 
SAN DIEGO, Jan. 17, 2018 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will host a webinar on Thursday, January 18, 2018 at 10 am EST (3pm BST/UK), presented by renowned immunologist, Dr. Jayant Thatte. Dr. Thatte will review currently available humanized models and describe innovative applications for preclinical immuno-oncology research.
The evaluation of immunotherapeutics is hindered by a lack of preclinical oncology models that exhibit functional human immunity. To overcome this obstacle, Crown Bioscience uses cutting-edge humanization protocols to develop innovative research solutions with reconstituted, functional human immune components. These humanized models can be combined with human cancer cell lines or patient-derived xenograft (PDX) models to help advance immuno-oncological drug and diagnostic development.
“I am excited to share the novel strategies Crown Bioscience has developed for applying humanized models in cancer pharmacology,” said Dr. Jayant Thatte, the General Manager of Crown Bioscience, San Diego. “The webinar will describe challenges of immunotherapeutic development, explore the pros and cons of using different model types and detail Crown Bioscience’s innovative portfolio of humanized solutions to help improve preclinical assessment of agents on human tumors within human immunity.”
For details or to register for this complimentary event, visit: Immuno-Oncology: Strategies for Applying Humanized Models
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries:
Jody Barbeau
Crown Bioscience Inc.
[email protected]
